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AbstrACt
Objectives To assess the prevalence of undiagnosed 
diabetes and pre- diabetes in the healthy population in the 
Mollerussa cohort. As a secondary objective, to identify the 
variables associated with these conditions and to describe 
the changes in glycaemic status after 1 year of follow- up 
in subjects with pre- diabetes.
Design Prospective observational cohort study.
setting General population from a semi- rural area.
Participants The study included 583 participants without 
a diagnosis of diabetes recruited between March 2011 and 
July 2014.
results The prevalence of undiagnosed diabetes was 
20, 3.4% (95% CI 2.6 to 4.2) and that of pre- diabetes 
was 229, 39.3% (37.3 to 41.3). Among those with pre- 
diabetes, 18.3% had isolated impaired fasting plasma 
glucose (FPG) (FPG: 100 to <126 mg/dL), 58.1% had 
isolated impaired glycated haemoglobin (HbA1c) (HbA1c 
5.7 to <6.5) and 23.6% fulfilled both criteria. Follow- up 
data were available for 166 subjects; 41.6%(37.8 to 
45.4) returned to normoglycaemia, 57.6% (57.8 to 61.4) 
persisted in pre- diabetes and 0.6% (0 to 1.2) progressed 
to diabetes. Individuals with pre- diabetes had worse 
cardiometabolic risk profiles and sociodemographic 
features than normoglycaemic subjects. In the logistic 
regression model, variables significantly associated with 
pre- diabetes were older age (OR; 95% CI) (1.033; 1.011 
to 1.056), higher physical activity (0.546; 0.360 to 0.827), 
body mass index (1.121; 1.029 to 1.222) and a family 
history of diabetes (1.543; 1.025 to 2.323). The variables 
significantly associated with glycaemic normalisation were 
older age (0.948; 0.916 to 0.982) and body mass index 
(0.779; 0.651 to 0.931).
Conclusions Among adults in our region, the estimated 
prevalence of undiagnosed diabetes was 3.4% and that 
of pre- diabetes was 39.3%. After a 1- year follow- up, a 
small proportion of subjects (0.6%) with pre- diabetes 
progressed to diabetes, while a high proportion (41.6%) 
returned to normoglycaemia. Individuals with pre- diabetes 
who returned to normoglycaemia were younger and had a 
lower body mass index.
bACkgrOunD
Diabetes mellitus, a public health concern 
with an increasing incidence worldwide, is a 
great threat to general health and is leading 
to increased morbidity and mortality. These 
effects are mainly occurring because diabetes 
is a disorder of glucose metabolism that 
affects multiple organ systems and is associ-
ated with various microvascular and macrovas-
cular complications and several non- vascular 
complications. Additionally, a large group 
of subjects do not fulfil the diabetes criteria 
but have intermediate glycaemic variables, 
between normal and diabetes, and are thus 
classified as having pre- diabetes. One of the 
most commonly used definitions of pre- 
diabetes is that of the 2010 American Diabetes 
Association (ADA) criteria:1 2 (a) impaired 
fasting plasma glucose (IFG), defined as 
fasting plasma glucose (FPG) between 100 
and <126 mg/dL (5.6 to 5.9 mmol/L); (b) 
impaired glucose tolerance (IGT), defined 
as a 2- hour plasma glucose value after a 75 g 
oral glucose tolerance test (OGTT) between 
140 and <200 mg/dL (7.8 to 11.0 mmol/L) 
or (c) glycated haemoglobin (HbA1c) levels 
between 5.7% and <6.5% (39 to 46 mmol/
mol).
strengths and limitations of this study
 ► This was a population- based study of a small co-
hort that included a representative sample of a non- 
previously studied population of a semi- rural area 
in Catalonia.
 ► We did not perform an oral glucose tolerance test, 
which is a common test in most studies but is a 
time- consuming and expensive procedure.
 ► The small number of cases of undiagnosed diabetes 
precluded further statistical analyses on this topic.
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Pre- diabetes is becoming increasingly important as it 
represents a high risk of developing type 2 diabetes (T2D) 
and cardiovascular diseases.2 3 Moreover, individuals with 
pre- diabetes are phenotypically quite similar to patients 
with T2D. That is, they tend to be older, with a higher 
body mass index (BMI) and higher blood pressure than 
people with normal glucose tolerance; in addition, they 
tend to have insulin resistance and dyslipidaemia.4 Addi-
tionally, multiple risk factors, such as family history, gesta-
tional diabetes and certain ethnicities as well as combined 
risk factors such as metabolic syndrome, are known to 
predispose subjects to a higher risk for pre- diabetes and 
its progression to T2D.5 Based only on IGT, the world-
wide prevalence of pre- diabetes among adults has been 
estimated by the International Diabetes Federation to be 
7.3% in 2017, with half of these individuals (49%) being 
younger than 50 years.6 The National Diabetes Statistics 
Report in the USA reported that the total crude preva-
lence of diabetes was 9.4% (30.3 million, 2017 US popu-
lation), with 23.8% undiagnosed and an additional 33.9% 
with pre- diabetes.7
In Spain, according to data from the  Di@ bet. es study, 
based on OGTT, FPG and HbA1c, 13.8% of the adult popu-
lation, adjusted for age and sex, had diabetes, and of these 
individuals up to 6% had undiagnosed diabetes. Further-
more, an additional 14.8% of individuals presented with 
some type of pre- diabetic state, 3.4% based on IFG, 9.2% 
based on IGT and 2.2% with disturbances in both, after 
adjusting for age and sex.8 9 According to the ADA, up 
to 70% of people with pre- diabetes will develop overt 
diabetes throughout their lives.10 11 Moreover, each year, 
5% to 10% of subjects with pre- diabetes will eventually 
develop overt diabetes, and according to some studies, 
this percentage can reach up to 18% per year; however, 
this rate may vary with the definition of pre- diabetes and 
population characteristics.12–15 It has been shown that 
over 3 to 5 years, approximately 25% of subjects progress 
to T2D, 25% return to a normal state of glucose tolerance 
and 50% remain in the pre- diabetic state.16 Thus, the 
early diagnosis and screening of pre- diabetes are essential 
steps towards the prevention of its progression or at least 
the delay of the onset of T2D.
The primary aim of this study was to assess the prev-
alence of undiagnosed diabetes and pre- diabetes in 
the healthy population in the Mollerussa cohort. As a 
secondary objective, we aimed to assess the variables asso-
ciated with these conditions and to describe the changes 
in glycaemic status after 1 year of follow- up in subjects 
with pre- diabetes.
MethODs
subjects
This was a prospective population- based cohort study 
from the semi- rural area of  Mollerussa in Catalonia 
(northeast Spain) selected between March 2011 and July 
2014. The description of the cohort and the procedures 
performed were initially published as a cohort profile.17 
Briefly, the database of the Catalan Health Institute 
(ICS) through its Primary Care Electronic Clinical 
Station (Estació Clínica Electronica d’Atenció Primaria 
– eCAP) was used to select the population sample. All 
population is passively included in the Primary Care Elec-
tronic Clinical record according to the Spanish health 
system, which is based on the principles of universality, 
free access, equity and fairness of financing.18 Then, 
from a total population of 24 666 potentially eligible 
individuals in the healthcare area (subjects older than 
25 years and attending any Primary Healthcare Centre 
in the same health area), 2226 subjects were randomly 
selected using a randomiser programme (SPSS software 
V.16.0 for Windows; SPSS), following the principles 
of simple random sampling, and were then invited to 
participate by telephone contact. Based on their willing-
ness to join the study, exclusion criteria, consent and 
baseline laboratory data, 594 subjects aged ≥25 years 
were finally included.17 The exclusion criteria included 
a previous diagnosis of diabetes (type 1 diabetes, T2D 
or any specific subtype of diabetes), treatment with oral 
antidiabetic drugs or the use of metformin for other 
conditions. In addition, subjects with cardiovascular 
disease (heart disease, heart failure, aortic stenosis), 
cancer, kidney disease, anaemia, hepatitis, gastroin-
testinal diseases, recent abdominal surgery, chronic 
obstructive pulmonary disease, chronic infectious 
diseases, use of systemic glucocorticoids or beta blockers 
or major psychiatric disorders with psychotic symptoms 
were excluded from the study. Subjects were considered 
to have hypertension or dyslipidaemia if they were using 
anti- hypertensive or lipid- lowering agents. Pre- diabetes 
was defined as any of the following abnormal glycaemic 
variables: FPG 100 to <126 mg/dL or HbA1c 5.7 to 
<6.5%; diabetes was defined as FPG ≥1256 mg/dL or 
HbA1c ≥6.5%. Normal glycaemic status was defined by 
FPG <100 mg/dL and HbA1c <5.7 according to the 2010 
ADA criteria.1 Eleven subjects without baseline HbA1c 
or FPG measurements were excluded. Subjects with pre- 
diabetes at baseline (n=229) underwent a second visit 12 
months after the baseline visit, and 166 (72.5%) of them 
had relevant information at follow- up.
A fasting blood sample was taken to determine 
glucose, HbA1c, total cholesterol, high density lipopro-
tein (HDL)- cholesterol, low density lipoprotein (LDL)- 
cholesterol, triglycerides, renal function and other 
parameters following standard protocols.17 The Fatty 
Liver Index (FLI) was calculated with the equation devel-
oped by Bedogni et al.19 Insulin resistance was calculated 
by the homeostatic model assessment-2 insulin resis-
tance (HOMA2- IR), beta cell function (HOMA2-ß) and 
insulin sensitivity (HOMA2- S) data were calculated with 
a HOMA2 calculator released by the Diabetes Trials Unit, 
University of Oxford: HOMA Calculator. This calculator 
is available at: http://www. dtu. ox. ac. uk/ homacalculator/ 
(updated 11 October 2017).20 The estimated glomerular 
filtration rate (eGFR) was calculated with the Chronic 
Kidney Disease Epidemiology Collaboration equation.21
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Figure 1 Flow diagram of subjects at baseline and after 
follow- up. HbA1c,glycated haemoglobin.
Sociodemographic variables were recorded by 
researchers following a protocol for the inclusion of 
patients using a standardised baseline questionnaire 
during the clinical interview. In all cases a physical exam-
ination (including weight, height, blood pressure and 
waist circumference) was carried out by trained research 
staff. Education level and physical activity were assessed 
according to the International Standard Classification 
of Education22 and the Spanish- validated International 
Physical Activity Questionnaire,23 respectively. We classi-
fied the education level as low level (studied until primary 
school) and high level (secondary high school education 
or higher). Physical activity was classified as sedentary or 
active (not regularly vs regularly active).
The study protocol was conducted following the 
Declaration of Helsinki. All study participants signed an 
informed consent form.
sample size
The sample size was determined based on an estimated 
pre- diabetes prevalence of 35.5% and 38% using HbA1c 
levels and the 2010 ADA criteria, respectively.1 24 25 It was 
estimated that a random sample of 505 subjects was suffi-
cient to assess an estimated prevalence of approximately 
30% with a 95% CI and an error of ±4%.17
statistical methods
Descriptive statistics of the mean (SD) or median (IQR) 
were estimated for quantitative variables with a normal 
or non- normal distribution, respectively. Qualitative vari-
ables were assessed using absolute and relative frequen-
cies. Normally distributed data were analysed using the 
Shapiro- Wilk test. Comparisons between groups of all 
variables were performed to evaluate the differences. 
Student’s t- test, analysis of variance, the Mann- Whitney 
test or the Kruskal- Wallis test were used to assess the 
differences between groups. The X2 test or Fisher’s exact 
test were used to determine differences in qualitative 
variables. Tukey's correction was applied to account for 
multiple tests. Multivariate logistic regression models 
were used to determine the association of variables with 
pre- diabetes, isolated FPG, isolated HbA1c and both FPG 
and HbA1c at baseline with covariables that were clini-
cally or statistically associated. In the pre- diabetes model, 
the variables used were age, sex, education level, physical 
activity, dyslipidaemia, hypertension, family history of 
diabetes, BMI, waist, glomerular filtration rate and Fatty 
Liver Index. A stepwise method with selection of vari-
ables by backward elimination was used to build the final 
logistic regression model to predict the normalisation 
of the glycaemic state; in all models, the goodness- of- fit 
assumption was tested by the Hosmer- Lemeshow test. The 
predictive accuracy of the logistic regression model for 
normalisation was checked by receiver- operating charac-
teristic (ROC) curves and the area under the ROC curve 
(AUCROC). ORs with corresponding 95% CIs are shown, 
and statistical significance was established as a p value 
<0.05. Data management and all analyses were performed 
using R statistical software, V.3.3.1, and SPSS software 
(V.22, IBM, SPSS, Chicago, Illinois, USA).
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study design 
and were not consulted to develop patient- relevant 
outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
results
Out of the 594 individuals recruited, complete data on 
FPG and HbA1c were available from 583 (98.1%). The 
prevalence of undiagnosed diabetes was 20 subjects, 3.4% 
(95% CI 2.7 to 4.2), and the prevalence of pre- diabetes 
was 229 subjects, 39.3% (37.3 to 41.3). Furthermore, the 
prevalence based on isolated FPG was 7.2%, and that 
based on isolated HbA1c was 22.8%, while based on the 
criteria of both FPG and HbA1c, the prevalence was 9.3% 
(figure 1).
The differences of clinical and sociodemographic char-
acteristics between normoglycaemic with pre- diabetic 
and diabetic groups are shown in table 1. Except for sex, 
family history of diabetes, current smoking status, alcohol 
consumption status, triglycerides and HDL- cholesterol 
levels, there were significant differences in the majority 
of parameters, including age and BMI, between the three 
groups.
We observed an association in age, BMI, waist circum-
ference, systolic and diastolic blood pressure, alcohol 
consumption status, hypertension, dyslipidaemia, 
triglycerides, total cholesterol, LDL- cholesterol, insulin 
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Table 1 Clinical and sociodemographic differences among glycaemic status groups of the Mollerussa cohort
Normoglycaemia
FPG <100 mg/dL 
and HbA1c <5.7%
Pre- diabetes
FPG 100 to 
<126 mg/dL, or 
HbA1c 5.7% to 
<6.5%
Diabetes
FPG≥126 mg/dL or 
HbA1c ≥6.5%
Mean difference NG vs 
PD (95% CI)
Mean difference NG vs 
DM (95% CI)
N 334 229 20 – –
Sex, women 193 (57.8%) 135 (59.0%) 13 (65.0%) 1.2 (-7.1 to 9.4) 7.2 (-14.3 to 28.8)
Age, years 47.1 (12.8) 54.6 (12.3) 61.2 (13.6) 7.5 (5.4 to 9.6) 14.2 (8.4 to 19.9)
BMI, kg/m2 25.3 (4.27) 27.5 (4.75) 30.2 (5.48) 2.1 (1.4 to 2.9) 4.9 (2.9 to 6.9)
BMI categories
  Normal weight 160 (50.0%) 67 (30.2%) 4 (20.0%) −18.6 (-26.6 to -10.7) −27.9 (-46.2 to -9.6)
  Overweight 120 (37.5%) 106 (47.7%) 5 (25.0%) 10.4 (2.1 to 18.6) −10.9 (-30.6 to 8.7)
  Obesity 40 (12.5%) 49 (22.1%) 11 (55.0%) 9.4 (3.1 to 15.8) 43.0 (20.9 to 65.1)
Waist, cm 91.9 (11.9) 97.0 (12.3) 101 (16.8) 5.1 (2.9 to 7.2) 9.3 (3.8 to 14.9)
SBP, mm Hg 119 (16.3) 126 (16.6) 130 (18.6) 6.7 (3.9 to 9.5) 10.9 (3.5 to 18.5)
DBP, mm Hg 75.7 (10.0) 78.2 (9.88) 78.0 (9.24) 2.5 (0.8 to 4.2) 2.3 (-2.2 to 6.8)
Hypertension 37 (11.1%) 49 (21.4%) 9 (45.0%) 10.3 (4.0 to 16.6) 33.9 (11.9 to 55.9)
Dyslipidaemia 27 (8.08%) 39 (17.0%) 5 (25.0%) 8.9 (3.2 to 14.6) 16.9 (-2.3 to 36.1)
Family history DM 94 (29.6%) 78 (37.0%) 8 (42.1%) 5.9 (-1.9 to 13.7) 11.8 (-10.1 to 33.9)
Education, high level 265 (82.6%) 145 (65.0%) 11 (55.0%) −16.0 (-23.6 to -8.4) −24.3 (-46.6 to -2.1)
Physical activity 243 (75.9%) 141 (63.2%) 10 (50.0%) −11.2 (-19.1 to -3.3) −22.7 (-45.2 to -0.3)
Current smoker 82 (24.6%) 63 (27.5%) 3 (15.0%) 3.0 (-4.4 to 10.4) −9.5 (-25.9 to 6.8)
Alcohol, g/day 8.33 (13.9) 12.3 (21.3) 10.6 (17.2) 4.0 (0.9 to 6.9) 2.2 (-5.8 to 10.3)
FPG, mg/dL 86.6 (7.04) 97.0 (11.2) 119 (15.2) 10.4 (8.8 to 11.9) 32.6 (28.4 to 36.8)
HbA1c, % 5.25 (0.26) 5.80 (0.29) 6.26 (0.54) 0.6 (0.5 to 0.6) 1.0 (0.9 to 1.1)
HbA1c, mmol/mol 33.8 (2.81) 39.9 (3.12) 45.0 (5.92) 6.1 (5.6 to 6.6) 11.1 (9.7 to 12.5)
eGFR mL/min/1.73 m2 96.6 (14.1) 90.4 (15.9) 85.5 (18.1) −6.2 (-8.7 to -3.7) −11.2 (-17.9 to -4.4)
Triglycerides, mg/dL 104 (90.0) 111 (63.2) 116 (47.3) 6.6 (-6.8 to 19.9) 11.2 (-24.7 to 47.1)
T- cholesterol, g/dL 197 (38.2) 205 (32.4) 214 (31.1) 7.9 (1.9 to 14.0) 16.9 (0.7 to 33.1)
HDL, mg/dL 58.7 (15.0) 58.8 (14.3) 64.6 (17.6) 0.1 (-2.4 to 2.6) 5.9 (-0.86 to 12.6)
LDL, mg/dL 119 (31.4) 125 (29.4) 126 (27.7) 6.3 (1.1 to 11.4) 7.5 (-6.3 to 21.4)
Insulin, µU/mL 7.99 (3.78) 10.1 (5.46) 16.2 (17.1) 2.1 (1.2 to 3.0) 8.2 (5.8 to 10.7)
Fatty Liver Index 34.0 (26.9) 44.3 (28.6) 59.4 (33.0) 10.3 (5.5 to 15.0) 25.4 (12.8 to 38.0)
HOMA2-β 104 (31.8) 97.7 (31.9) 89.0 (48.4) −6.3 (-11.8 to -0.8) −14.9 (-29.7 to -0.2)
HOMA2- S 118 (52.1) 94.0 (43.4) 63.3 (26.7) −23.8 (-32.0 to -15.6) −54.4 (-76.3 to -32.6)
HOMA2- IR 1.03 (0.48) 1.33 (0.72) 2.16 (2.08) 0.3 (0.2 to 0.4) 1.1 (0.8 to 1.4)
Mean (SD) and n (%).
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; 
HbA1c, glycated haemoglobin; HDL, high- density lipoprotein cholesterol; HOMA2-ß, homeostatic model assessment-2 beta cell function; HOMA2- 
IR, homeostatic model assessment-2 insulin resistance; HOMA2- S, homeostatic model assessment-2 insulin sensitivity; LDL, low- density lipoprotein 
cholesterol; NG, normoglycaemia; PD, pre- diabetes; SBP, systolic blood pressure; T- cholesterol, total cholesterol.
test, FLI and HOMA2- IR, which were higher in individ-
uals with pre- diabetes than in individuals with normogly-
caemia and were higher in the diabetic group than in the 
pre- diabetic group. On the other hand, physical activity, 
education level, eGFR, HOMA2-β and HOMA2- S exhib-
ited a negative trend between the same groups. In the 
pre- diabetic group, 41.9% had impaired FPG and 81.7% 
had impaired HbA1c. On the other hand, among the 
newly identified diabetic subjects, up to 80% met the FPG 
criteria and 85% met the HbA1c criteria. The prevalence 
of pre- diabetes increased with increasing age, with 
percentages of 17.4%, 28.6%, 46.4%, 50% and 52.9% in 
participants aged <35 years, 36 to 45 years, 46 to 55 years, 
56 to 65 years and >65 years, respectively. Regarding 
BMI categories of normal weight (BMI <25 kg/m2), over-
weight (BMI 25 to 29.9 kg/m2) and obese (BMI >30 kg/
m2), the prevalence of pre- diabetes was 29%, 45.9%, and 
49%, respectively (online supplementary file 1 figure 1).
Table 2 shows the characteristics of pre- diabetic indi-
viduals by glycaemic state: isolated FPG, isolated HbA1c 
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Table 2 Clinical and sociodemographic characteristics by glycaemic status of the individuals with pre- diabetes
Impaired HbA1c 
5.7% to <6.5%
Impaired FPG
100 to <126 mg/dL
HbA1c 5.7% to <6.5% 
and FPG 100 to 
<126 mg/dL P overall
P HbA1c 
vs FPG
P HbA1c 
vs both
P FPG vs 
both
N 133 42 54 – – – –
Sex, women 84 (63.2%) 19 (45.2%) 32 (59.3%) 0.12 0.181 0.74 0.369
Age, years 53.4 (12.4) 50.6 (11.8) 60.6 (10.5) <0.001 0.388 0.001 <0.001
BMI, kg/m2 25.8 (24.5 to 28.9) 27.8 (24.5 to 30.6) 27.5 (25.6 to 30.5) 0.056 0.534 0.036 0.534
BMI categories 0.018 0.107 0.05 0.032
  Normal weight 43 (33.1%) 16 (41.0%) 8 (15.1%)
  Overweight 64 (49.2%) 12 (30.8%) 30 (56.6%)
  Obesity 23 (17.7%) 11 (28.2%) 15 (28.3%)
Waist, cm 95.0 (88.0 to 102) 98.0 (90.0 to 106) 101 (95.0 to 107) 0.008 0.232 0.006 0.333
SBP, mm Hg 124 (16.1) 129 (15.5) 128 (18.4) 0.169 0.296 0.29 0.991
DBP, mm Hg 78.0 (9.44) 79.5 (12.0) 77.9 (9.39) 0.674 0.675 0.999 0.723
Hypertension 21 (15.8%) 9 (21.4%) 19 (35.2%) 0.014 0.542 0.019 0.32
Dyslipidaemia 25 (18.8%) 4 (9.52%) 10 (18.5%) 0.358 0.515 1 0.515
Family history DM 43 (34.1%) 18 (48.6%) 17 (35.4%) 0.265 0.471 1 0.471
Education, high level 91 (69.5%) 23 (59.0%) 31 (58.5%) 0.252 0.455 0.455 1
Physical activity 88 (67.2%) 21 (53.8%) 32 (60.4%) 0.281 0.547 0.68 0.68
Current smoker 38 (28.6%) 14 (33.3%) 11 (20.4%) 0.338 0.693 0.496 0.496
Alcohol, g/day 2.92 (0.00 to 15.2) 7.42 (0.90 to 16.3) 1.53 (0.00 to 17.9) 0.369 0.336 0.735 0.336
FPG, mg/dL 89.2 (6.89) 106 (4.97) 109 (5.96) <0.001 <0.001 <0.001 0.14
HbA1c, % 5.80 (5.70 to 6.00) 5.40 (5.40 to 5.57) 5.95 (5.80 to 6.10) <0.001 <0.001 <0.001 <0.001
HbA1c, mmol/mol 39.9 (38.8 to 42.1) 35.5 (34.7 to 37.4) 41.5 (39.9 to 43.2) <0.001 <0.001 <0.001 <0.001
eGFR, mL/min/1.73 m2 93.6 (79.6 to 103) 93.2 (79.7 to 107) 89.3 (73.1 to 97.2) 0.076 0.556 0.073 0.073
Triglycerides, mg/dL 88.0 (72.0 to 134) 86.5 (67.0 to 130) 106 (74.5 to 132) 0.332 0.729 0.304 0.304
Total cholesterol, mg/dL 205 (34.5) 209 (28.6) 203 (29.8) 0.689 0.767 0.947 0.677
HDL- cholesterol, mg/dL 58.0 (51.0 to 69.0) 52.0 (45.0 to 65.8) 57.0 (51.0 to 66.0) 0.128 0.141 0.755 0.18
LDL- cholesterol, mg/dL 125 (32.2) 133 (25.5) 120 (23.5) 0.114 0.278 0.593 0.096
Insulin, µU/mL 8.00 (6.10 to 10.0) 9.90 (6.90 to 15.9) 10.9 (7.90 to 15.6) <0.001 0.01 <0.001 0.577
Fatty Liver Index 34.4 (16.9 to 59.2) 42.2 (17.7 to 73.6) 53.8 (32.2 to 73.0) 0.016 0.373 0.011 0.378
HOMA2-β 96.6 (81.5 to 122) 81.7 (64.5 to 118) 82.8 (63.0 to 108) 0.001 0.034 0.002 0.693
HOMA2- S 98.0 (77.2 to 127) 75.0 (47.2 to 107) 67.5 (47.5 to 91.3) <0.001 0.003 <0.001 0.564
HOMA2- IR 1.00 (0.80 to 1.30) 1.30 (0.90 to 2.15) 1.50 (1.10 to 2.10) <0.001 0.005 <0.001 0.545
Significant values are shown in bold. Mean (SD), median (IQR) and n (%).
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FPG, fasting plasma 
glucose; HbA1c, glycated haemoglobin; HDL, high- density lipoprotein; HOMA2-β, homeostatic model assessment-2 beta cell function; HOMA2- IR, 
homeostatic model assessment-2 insulin resistance; HOMA2- S, homeostatic model assessment-2 insulin sensitivity; LDL, low- density lipoprotein; 
SBP, systolic blood pressure.
and both altered FPG and HbA1c. Thus, among the 229 
subjects with pre- diabetes, 42 (18.3%) had abnormal 
isolated FPG, 133 (58.1%) had abnormal isolated HbA1c 
and 54 (23.6%) had both abnormal FPG and HbA1c. 
Patients with both abnormal FPG and HbA1c were older, 
had larger waist circumferences, had increased FLI and 
HOMA2- IR, were more likely to be overweight or obese 
and have hypertension and had lower HOMA2- S. The 
isolated FPG group had a higher proportion of subjects 
with a family history of diabetes, higher alcohol consump-
tion, higher levels of total cholesterol and LDL- cholesterol 
and lower levels of HDL- cholesterol, although none of 
these differences were statistically significant. Finally, 
the isolated HbA1c group had an elevated HOMA2-β. 
Although there were no statistically significant differ-
ences, the proportion of men was higher in the isolated 
FPG group, whereas the proportion of women was higher 
in the isolated HbA1c and both FPG and HbA1c groups. 
Among the three groups, no statistically significant differ-
ences were found regarding the following variables: sex, 
dyslipidaemia, family history of diabetes, education level, 
physical activity, current smoking status, alcohol consump-
tion, triglycerides, total cholesterol, HDL- cholesterol or 
LDL- cholesterol.
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Table 3 Outcomes at follow- up of patients with different altered glucose metabolism statuses at baseline
Variables Baseline N with follow- up
Follow- up
Normalised Persisted Progressed
Pre- diabetes 229 (39.3%) 166 (90.7%) 52 (41.6%) 112 (57.8%) 2 (0.6%)
Isolated FPG 42 (7.2%) 3 (1.8%) 1 (33.3%) 1 (33.3%) 1 (33.3%)
Isolated HbA1c 133 (22.8%) 114 (68.7%) 47 (41.3%) 67 (58.7%) 0 (0%)
Both altered 54 (9.3%) 49 (29.5%) 4 (8.2%) 44 (89.8%) 1 (2%)
FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.
Figure 2 Multivariate logistic regression models: (a) Model of pre- diabetes versus normoglycaemic state in the Mollerussa 
cohort at baseline. Significant p values are shown in BOLD. Hosmer- Lemeshow test p=0.295. (b) Model of normalised versus 
persisted in subjects with follow- up data. Significant p values are shown in BOLD. Hosmer- Lemeshow test p=0.931. eGFR, 
estimated glomerular filtration rate.
Pre-diabetes follow-up
Of the 229 individuals with pre- diabetes at baseline, 166 
(72.5%) had clinical and laboratory data after 12 months 
of follow- up. Of them, 52 (41.6%) returned to a normal 
glycaemic status, 112 (57.6%) persisted in their state of 
pre- diabetes and only 2 (0.6%) progressed to diabetes. 
Table 3 shows the outcome of the follow- up of the isolated 
FPG, HbA1c and both FPG and HbA1c groups.
Association of pre-diabetes with glycaemic status
The multivariate logistic regression model of pre- 
diabetes versus normoglycaemia showed that the vari-
ables associated with pre- diabetes were older age (OR; 
95% CI) (1.033; 1.011 to 1.056), higher physical activity 
levels (0.546; 0.360 to 0.827), higher BMI (1.121; 1.029 
to 1.222) and a family history of diabetes (1.543; 1.025 
to 2.323) (figure 2A). The models for isolated FPG 
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alterations, isolated HbA1c alterations and both FPG and 
HbA1c alterations are shown in online supplementary file 
2 tables 1, 2 and 3, respectively. The variables associated 
with isolated FPG were older age (1.032; 1.008 to 1.057), 
higher physical activity levels (0.535; 0.318 to 0.899) and 
a family history of diabetes (1.798; 1.067 to 3.028). On the 
other hand, the only variable associated with impaired 
HbA1c was older age (1.048; 1.029 to 1.067). Finally, in 
the model for altered FPG and HbA1c, the variables asso-
ciated were older age (1.056; 1.026 to 1.086) and high FLI 
(1.031; 1.002 to 1.061).
Prediction of normalisation
Logistic regression model, as described in the methods 
section, starting with the variables age, sex, waist circum-
ference, BMI, hypertension, physical activity, family 
history of diabetes, education level, total cholesterol, 
HDL- cholesterol, FLI and HOMA2- IR, was performed to 
identify factors independently associated with the predic-
tion of glycaemic status normalisation (online supplemen-
tary file 2 table 4). The variables that predicted glycaemic 
normalisation were older age (0.948; 0.916 to 0.982) and 
BMI (0.779; 0.651 to 0.931) (figure 2B); this model had 
a good predictive ability (AUCROC 0.77; p<0.001) (online 
supplementary file 3 figure 2).
DisCussiOn
We found that the prevalence of undiagnosed diabetes was 
3.4%, and the prevalence of pre- diabetes was 39.3% in this 
semi- rural population in Catalonia (northeast Spain). The 
prevalence of pre- diabetes was three- fold higher based on 
HbA1c than that based on FPG. Subjects with pre- diabetes 
defined by both HbA1c and FPG criteria had unfavourable 
clinical and sociodemographic profiles related to increased 
cardiovascular risk. These factors were older age; abdom-
inal obesity; higher triglycerides; increased FLI and a higher 
proportion of overweight, obesity and hypertension. In our 
population, age was the variable most strongly associated 
with pre- diabetes based on all specific glycaemic status vari-
ables: isolated impaired FPG, isolated impaired HbA1c or 
both impaired FPG and HbA1c. Other variables associated 
with pre- diabetes were lower physical activity levels, a family 
history of diabetes and obesity. Finally, the characteristics 
related to normalisation at follow- up were younger age and 
lower BMI.
The prevalence of pre- diabetes and undiagnosed diabetes 
in our healthy population were within the ranges found in 
other population studies defining pre- diabetes based on 
the 2010 ADA criteria, using FPG and/or HbA1c. Among 
these studies, a large national Chinese study (with 170 287 
subjects) showed a prevalence of pre- diabetes of 35.7% and 
a prevalence of undiagnosed diabetes of 6.9%.26 In a study 
of the Caribbean population, the corresponding figures 
were 44.1% for pre- diabetes and 7.3% for undiagnosed 
diabetes.27 In England, based on HbA1c levels, the pre- 
diabetes prevalence was 35.5% in the adult population in 
2011.24 In these studies, the prevalence of pre- diabetes was 
higher in older, overweight and obese participants.24 26 27 
Many other studies found this relationship of age and obesity 
with the risk and incidence of diabetes.28–31
In the 1999 to 2002 National Health and Nutrition Exam-
ination Survey (NHANES), the prevalence of undiagnosed 
diabetes was 2.8%, and up to 26% of the participants had 
IFG.32 However, the age- standardised prevalence of pre- 
diabetes based on HbA1c and FPG combined was similar 
in the periods between 1999 and 2002 and 2003 and 2006 
at 29.2% and 29.3%, respectively, but increased signifi-
cantly to 36.2% in the period between 2007 and 2010.33 
This prevalence continued to increase to as high as 38% 
in 2012 among adults from the USA.25 The change in the 
prevalence of pre- diabetes over time occurred because of 
a significant change in elevated HbA1c, whereas the preva-
lence based on elevated FPG was similar over this period.33 
Thus, in our population, as in the NHANES study, HbA1c 
was the most significant contributor to pre- diabetes preva-
lence, followed by FPG, which is in concordance with the 
findings in the Caribbean population27 and discordant 
with the reports from the NHANES study between 2011 
and 2014 in which they reported that FPG was the most 
significant contributor to pre- diabetes prevalence followed 
by HbA1c.34 Our results show that individuals with isolated 
impaired HbA1c when diagnosed with pre- diabetes might 
have a slightly better cardiometabolic risk profile than 
those with isolated FPG, while those individuals with both 
impaired FPG and HbA1c had the worst cardiovascular 
risk. These results are in line with the findings of the 
prospective observational study in the primary care setting 
of a Spanish cohort with pre- diabetes (PREDAPS) of our 
group.35 36
Additionally, two meta- analyses found that among indi-
viduals with pre- diabetes based on the ADA criteria, all- 
cause and cardiovascular disease (CVD) mortality were 
increased37 and that the risk of cardiovascular disease 
increased independently of the glucose assessment in 
comparison to the risk of normoglycaemic subjects.38 
Moreover, a recent study concluded that those who 
returned to normoglycaemia from FPG- defined or 
HbA1c- defined pre- diabetes were not at reduced risk 
of future CVD or death.39 Studies of shorter duration, 
over 3 to 5 years, have shown that approximately 25% of 
subjects progress to diabetes, 25% return to a normal state 
of glucose tolerance and 50% remain in the pre- diabetic 
state;16 after 1 year, 18.8% of subjects with pre- diabetes 
returned to normoglycaemia and approximately 30% 
with abnormal FPG, 29.1% with abnormal HbA1c and 
7.6% with abnormalities in both FPG and HbA1c returned 
to a normal state of glucose tolerance.40 In our findings 
from a 1- year follow- up, the rate of reversion from pre- 
diabetes to normoglycaemia was approximately 40%, and 
approximately 60% of participants remained in the pre- 
diabetic state. On the other hand, lifestyle modifications, 
such as weight loss and increased physical activity, among 
other factors associated with pre- diabetes, reduced the 
risk of diabetes among these subjects.13 41 According to 
these reports, in our study, lower BMI was a factor that was 
copyright.
 o
n
 January 21, 2020 at Universitat de Lleida. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033332 on 20 January 2020. Downloaded from 
8 Falguera M, et al. BMJ Open 2020;10:e033332. doi:10.1136/bmjopen-2019-033332
Open access 
independently associated with the normalisation of the 
glycaemic state, and an active lifestyle decreased the risk 
of having pre- diabetes.
The results of this study need to be interpreted in light 
of its strengths and weaknesses. First, the number of partici-
pants in our study is smaller in comparison to other studies. 
In addition, the study may not be representative of urban 
areas in our region. Thus, the results may not be general-
isable to other territories with different population charac-
teristics in our country. However, the Mollerussa cohort is 
a representative sample of the region, which is a specific 
semi- rural area that has never been specifically investi-
gated. Second, our study sample is probably healthier 
than the general population, as we excluded subjects 
with already known diabetes and other comorbidities, a 
lower number of subjects were counted in the denomi-
nator, thus resulting in a higher prevalence of this condi-
tion. Third, we did not assess glucose tolerance through 
an oral glucose tolerance test, which is common in most 
population studies. Although this assay is sensitive, it is 
also less specific for identifying subjects who could develop 
diabetes.42 Furthermore, the oral glucose tolerance test has 
a low reproducibility and is a rather time- consuming and 
expensive procedure.9 43 Conversely, HbA1c and FPG are 
cost- effective and more convenient for patients. Currently, 
FPG is an accepted screening method to detect diabetes 
and pre- diabetes. HbA1c improves the sensitivity of FPG in 
the detection of early T2D in high- risk subjects32 44 and is a 
better predictor of CV events than FPG.45 Fourth, we only 
followed up those participants with pre- diabetes. Thus, we 
could not analyse the probability of changing from normo-
glycaemia to pre- diabetes or diabetes in this study. Finally, 
it is probable that the use of the WHO pre- diabetes criteria 
in our study would have resulted in a smaller proportion 
of subjects who returned to a normal glycaemic state. The 
WHO established a normal concentration of FPG between 
110 and <126 mg/dL.46
Conclusions
For the first time, our study provides information on the 
prevalence of diabetes and pre- diabetes in the Mollerussa 
healthcare area, a Mediterranean semi- rural area in 
northeast Spain. Individuals with pre- diabetes had a more 
unfavourable cardiometabolic risk profile than normogly-
caemic subjects. Moreover, individuals with abnormalities 
in both criteria used to diagnose pre- diabetes had the worst 
risk profile. Finally, after 1 year of follow- up, few people 
progressed to diabetes, while more than 40% returned to 
a normal glycaemic state and nearly 60% persisted in the 
pre- diabetic state. These results suggest that the use of both 
FPG and HbA1c criteria in clinical practice could help 
identify people with high diabetes and cardiovascular risk. 
Moreover, the identification of individuals with pre- diabetes 
provides an opportunity for intervention through lifestyle 
modification and pharmacological treatments not only to 
reduce the development of diabetes.
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